ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Carboplatin

Also written as “carboplatin”, “Pemetrexed/Carboplatin” and “CARBOPLATIN”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Breast Neoplasms · Small Cell Lung Carcinoma · Neoplasms, led by 31 companies.

Drug pageCarboplatin: every studyMany companies study it; this page follows only the 89 they lead. All 1,229 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 24, 200989 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only300 open or runningphase 4since Nov 24, 2009Apr 30, 2002none ahead
Bristol-Myers Squibb140 open or runningphase 4since May 28, 2014Sep 13, 2001none ahead
Sanofiits history only70 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Instituteits history only31 open or runningphase 2since Nov 2, 2005Nov 2, 2005none ahead
Swedish Orphan Biovitrumits history only30 open or runningphase 3since Feb 5, 2003Feb 5, 2003none ahead
AGO Researchits history only20 open or runningphase 3since Apr 16, 2013Apr 16, 2013none ahead
CarTheraits history only21 open or runningphase 3since Jun 5, 2023Nov 13, 2018Jan 28, 2028phase 3 · NCT05902169
Eisaiits history only20 open or runningphase 3since Dec 31, 2002Dec 31, 2002none ahead
InSightecits history only20 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Ionis Pharmaceuticalsits history only20 open or runningphase 3since Jun 6, 2001Jun 6, 2001none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Daiichi Sankyo, AstraZeneca, Merck, Parexel, Arcus Biosciences, Ono Pharmaceutical, Pfizer, Novotech (Australia) Pty, WuXi CDS Clinical Research (Shanghai), Valerio Therapeutics, Ortho Biotech, Tibotec Pharmaceutical and Medarex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2001First study: phase 1 study in Unspecified Childhood Solid Tumor, Protocol SpecificFirst studyNCT00024284 · United States, Canada
  2. May 2, 2002Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00035152 · 444 enrolled · United States
  3. Apr 2, 2003Phase 2 study in NeoplasmsNCT00057473 · United States
  4. Oct 4, 2004Phase 2 study in Breast NeoplasmsNCT00093145 · 32 enrolled · United States
  5. Dec 1, 2006Phase 1 study in Fallopian Tube NeoplasmsNCT00407407 · 6 enrolled · United States
  6. Nov 20, 2008Phase 1 study in Advanced MelanomaNCT00796991 · 72 enrolled · United States
  7. Oct 5, 2009Phase 2 study in Pediatric Solid TumorsNCT00990912 · 20 enrolled
  8. Jun 17, 2013Phase 3 study in Breast NeoplasmsNCT01881230 · 191 enrolled · United States, Australia, Austria and more
  9. May 28, 2014Phase 4 study in Carcinoma, Non-Small-Cell LungNCT02151149 · 143 enrolled · United States
  10. Nov 10, 2014Phase 2 study in Carcinoma, Non-Small-Cell LungNCT02289456 · 40 enrolled · United States
  11. Jun 18, 2015Phase 3 study in Carcinoma, Non-Small-Cell LungNCT02477826 · 2,747 enrolled · United States, Argentina, Australia and more
  12. Dec 16, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungNCT02998528 · 505 enrolled · United States, Argentina, Brazil and more
  13. Jan 7, 2021Phase 2 study in Small Cell Lung CarcinomaNCT04702880 · 135 enrolled · United States, Australia, Belgium and more
  14. Nov 18, 2021Phase 2 study in Mesothelioma, MalignantNCT05136677 · 102 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05136677Mesothelioma, Malignant · China2CompletedNov 12, 2025102
NCT04702880Small Cell Lung Carcinoma · United States, Australia, Belgium and more2CompletedMay 22, 2025135
NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3CompletedSep 8, 2021505
NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedOct 25, 20242,747
NCT02289456Carcinoma, Non-Small-Cell Lung · United States2CompletedFeb 22, 201740
NCT02151149Carcinoma, Non-Small-Cell Lung · United States4CompletedJul 14, 2017143
NCT01881230Breast Neoplasms · United States, Australia, Austria and more3CompletedOct 28, 2016191
NCT00990912Pediatric Solid Tumors2CompletedNov 200520
NCT00796991Advanced Melanoma · United States1CompletedNov 200972
NCT00407407Fallopian Tube Neoplasms · United States1TerminatedFeb 1, 20086
NCT00093145Breast Neoplasms · United States2CompletedOct 1, 200832
NCT00057473Neoplasms · United States2CompletedFeb 2004
NCT00035152Carcinoma, Non-Small-Cell Lung · United States3Completed444
NCT00024284Unspecified Childhood Solid Tumor, Protocol Specific · United States, Canada1CompletedDec 2003

How it is read

Names in the registry

  • “Carboplatin”, 110 entries
  • “carboplatin”, 38 entries
  • “Pemetrexed/Carboplatin”, 2 entries
  • “CARBOPLATIN”, 2 entries
  • “Carboplatin/Paclitaxel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.